Michael Gelband’s aTyr Pharma ATYR Stock Holding History

Michael Gelband’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48,227	Closed	-$146K	–	2058
2025 Q1	$146K	Buy	48,227 +31,441	+187%	+$115K	﹤0.01%	1325
2024 Q4	$61K	Buy	+16,786	New	+$50.8K	﹤0.01%	1420
2022 Q2	–	Sell	-13,456	Closed	-$72K	–	2542
2022 Q1	$72K	Buy	+13,456	New	+$76.2K	﹤0.01%	2035
2021 Q2	–	Sell	-11,066	Closed	-$49K	–	2887
2021 Q1	$49K	Buy	+11,066	New	+$52K	﹤0.01%	2032

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's ATYR Position: Q2 2025 in Review

Michael Gelband sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 48,227 shares — an estimated $146K sold.

Michael Gelband first reported a position in ATYR in Q1 2021 and held it in 4 quarters. The position peaked at $146K in Q1 2025. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

Michael Gelband reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
Michael Gelband sold 48,227 aTyr Pharma shares in Q2 2025, an estimated $146K.
Michael Gelband first reported a position in aTyr Pharma in Q1 2021 and held it in 4 quarters.
Michael Gelband's aTyr Pharma position peaked at $146K in Q1 2025.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.